Somatostatin Analogue Treatment Increases AIP Protein Expression in Somatotroph Tumours from Patients with Acromegaly and in GH3 Cells in vitro.

Somatostatin Analogue Treatment Increases AIP Protein Expression in Somatotroph Tumours from Patients with Acromegaly and in GH3 Cells in vitro.

Bibliographic Details
Main Authors:	Chahal, H, Ansorge, O, Karavitaki, N, Leontiou, C, Carlsen, E, Wass, J, Grossman, AB, Korbonits, M
Format:	Journal article
Language:	English
Published:	2011

Similar Items

AIP Mediates the Effects of Somatostatin Analogues in Acromegaly - Evidence from Clinical and Experimental Studies.
by: Chahal, H, et al.
Published: (2010)

Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway.
by: Chahal, H, et al.
Published: (2012)

Acromegaly: Treatment with somatostatin analogs
by: Karavitaki, N, et al.
Published: (2005)

Pituitary imaging using a labelled somatostatin analogue in acromegaly.
by: Ur, E, et al.
Published: (1992)

The role of somatostatin analogues in the treatment of neuroendocrine tumours.
by: Grozinsky-Glasberg, S, et al.
Published: (2008)

Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas.
by: Larkin, S, et al.
Published: (2013)

Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.
by: Grozinsky-Glasberg, S, et al.
Published: (2008)

The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
by: Karavitaki, N, et al.
Published: (2005)

Sequence analysis of the catalytic subunit of PKA in somatotroph adenomas.
by: Larkin, S, et al.
Published: (2014)

Increased population risk of AIP-related acromegaly and gigantism in Ireland.
by: Radian, S, et al.
Published: (2016)

Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
by: Jenkins, P, et al.
Published: (2000)

Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
by: Kaltsas, G, et al.
Published: (2005)

Antiangiogenic effects of somatostatin analogues.
by: García de la Torre, N, et al.
Published: (2002)

AIP, a Protein Mutated in Familial Acromegaly, Plays a Role in the Regulation of Cell Proliferation and Shows Cell-Type Specific Subcellular Localisation
by: Leontiou, C, et al.
Published: (2009)

Acromegaly and anaplastic astrocytoma: coincidence or pathophysiological relation?
by: Fernandez, A, et al.
Published: (2008)

Sequence analysis of the PRKAR1A gene in sporadic somatotroph and other pituitary tumours.
by: Kaltsas, G, et al.
Published: (2002)

Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours.
by: Hubina, E, et al.
Published: (2006)

Pegvisomant: a new treatment modality for acromegaly.
by: Karavitaki, N, et al.
Published: (2004)

Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
by: Ur, E, et al.
Published: (1993)

Rapid desensitisation of the GH secretagogue (ghrelin) receptor to hexarelin in vitro.
by: Orkin, R, et al.
Published: (2003)

GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence.
by: Arnold, JR, et al.
Published: (2009)

The Pathogenic Role of AIP Mutations - The Importance of the Integration of Clinical, Experimental and Modeling Data on Advising Patients and Their Families with Pituitary Adenoma Predisposition.
by: Trivellin, G, et al.
Published: (2010)

Imaging neuroendocrine tumours with radiolabelled somatostatin analogues and X-ray computed tomography: a comparative study.
by: King, C, et al.
Published: (1993)

Acute octreotide suppression test (100 mu g sc): a valuable tool for predicting the long-term response to the long-acting somatostatin analogs in patients with active acromegaly
by: Karavitaki, N, et al.
Published: (2005)

Low rate of germline AIP mutations in patients with apparently sporadic pituitary adenomas before the age of 40: a single-centre adult cohort.
by: Preda, V, et al.
Published: (2014)

DEPOT BROMOCRIPTINE IN THE TREATMENT OF PROLACTINOMAS AND ACROMEGALY
by: Grossman, A, et al.
Published: (1985)

Depot-bromocriptine treatment for prolactinomas and acromegaly.
by: Grossman, A, et al.
Published: (1986)

GH feedback occurs through modulation of hypothalamic somatostatin under cholinergic control: studies with pyridostigmine and GHRH.
by: Ross, R, et al.
Published: (1987)

New treatments for acromegaly.
by: Wass, J, et al.
Published: (1998)

AIP mutation in pituitary adenomas in the 18th century and today.
by: Chahal, H, et al.
Published: (2011)

Hypercalcaemia in acromegaly is not always due to men-1
by: Zabuliene, L, et al.
Published: (2005)

The interaction of growth hormone releasing hormone and somatostatin in the generation of a GH pulse in man.
by: Hindmarsh, P, et al.
Published: (1991)

Acromegaly, colonic polyps and carcinoma.
by: Jenkins, P, et al.
Published: (1997)

GH replacement does not increase the risk of recurrence in patients with craniopharyngioma.
by: Karavitaki, N, et al.
Published: (2006)

Evidence for the effectiveness of radiotherapy in the treatment of acromegaly.
by: Wass, J
Published: (1997)

Long-term effects of radiotherapy for acromegaly.
by: Wass, J
Published: (1996)

Radiotherapy in acromegaly: a protagonists viewpoint.
by: Wass, J
Published: (2003)

The pathology of median neuropathy in acromegaly.
by: Jenkins, P, et al.
Published: (2000)

Brief Report: AIP Mutation in Pituitary Adenomas in the 18th Century and Today.
by: Chahal, H, et al.
Published: (2011)

Guidelines for acromegaly management.
by: Melmed, S, et al.
Published: (2002)